FDA
-
-
-
-
-
-
-
RedHill Biopharma's (RDHL) Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs
-
-
-
-
-
-
-
Gilead Sciences (GILD) to acquire CymaBay Therapeutics (CBAY) in $4.3bn cash deal
-
-
-
-
-
-
-
U.S. FDA Approves Label Update for Kite’s Yescarta® CAR T-Cell Therapy to Include Overall Survival Data
-
-
-
-
-
-
-
Kite (GILD) and Arcellx (ACLX) Expand Strategic Partnership
-
-
-
-
-
-
-
Gilead to Present Latest Innovative Virology Data on Current and Potentially Transformative Therapies Across HIV and COVID-19 at IDWeek 2023
-
-
-
-
-
-
-
Gilead Sciences Announces Second Quarter 2023 Financial Results
-
-
-
-
-
-
-
Gilead's(GILD) Kite's Tecartus CAR T-cell Therapy Demonstrates 78% Complete Response Rate and 90% Overall Response Rate
-
251,622 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All